Platinum based drugs have been used for years in the treatment of tumors, but these drugs are less than ideal because of their toxicity. A search for other metal-based drugs has led researchers to indazolium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] (KP1019), a novel ruthenium based drug. KP1019 has undergone phase I clinical trials with no dose limiting toxicity. It has been shown that the drug inhibits cell growth, damages DNA, and causes cell death in both cancerous and yeast cells. KP1019 uptake has been observed in mammalian cells, and the purpose of this study was to show uptake in yeast. After a two hour incubation, yeast cells that were treated with KP1019 showed measurable uptake of ruthenium as measured by atomic absorption spectroscopy. This experiment supports the theory that yeast cells are an acceptable model organism to study KP1019.

Quantifying the uptake of KP1019 in yeast cells

245th National Meeting (2013)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.